BARDA DRIVe Mitigating Long-term Effects (MILE) of respiratory distress

Due Date: 30 April 2022 5:00 PM ET on Government Organization: BARDA Description: Office of Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation & Ventures (DRIVe) Special Instructions 015 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Opportunity at BARDA DRIVe. If you have companies that you think are of interest, please send them directly to the HostTx team. Area of Interest #12: Mitigating Long-term Effects (MILE) of respiratory distress

Category: Opportunity

DoD Communities Of Interest: Biomedical ASBREM

Subject: BARDA DRIVe Mitigating Long-term Effects (MILE) of respiratory distress

Due Date: 30 April 2022 5:00 PM ET on

Government Organization: BARDA

Description:

Office of Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation & Ventures (DRIVe)

Special Instructions 015 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002

 

Below please find summaries a funding opportunity at BARDA DRIVe. If you have companies that you think are of interest, please send them directly to the HostTx team.

Area of Interest #12: Mitigating Long-term Effects (MILE) of respiratory distress

Technical POC:HostTx@hhs.gov

Overview: DRIVe is interested in further study of host therapeutic product candidates that may be implemented early in the progression of acute lung injury to specifically reduce the long-term morbidity and mortality resulting from the initial injury or infectious insult. Of specific interest are candidates already in development for treating lung injury or another acute indication that can be adapted to include additional clinical research and analytics beyond their original primary/secondary endpoint(s) to explore impact on long-term outcomes as additional parameters. Analyses should assess the potential of the treatment to restore and/or maintain baseline health characteristics and/or to reduce hospital readmission.

Out of scope:

• Pathogen-based or pathogen targeted products.

• Supportive care technologies that do not specifically improve clinical outcomes for patients.

• Exploratory research with no near-term translational application.

• Studies only targeting long-term outcomes of respiratory distress from chronic conditions, e.g. asthma, COPD.

• Product candidates that are intended for administration after the acute phase of injury (i.e. post-discharge).

Questions:

Emil Runge

First Flight Venture Center

(404) 668-2136

Website: https://drive.hhs.gov/partner.html

Questions or assistance, contact:
North Carolina Defense Technology Transition Office (DEFTECH)

 

Dennis Lewis
lewisd@ncmbc.us
703-217-3127

Bob Burton
burtonr@ncmbc.us
910-824-9609

North Carolina Defense Technology Transition Office | PO Box 1748, Fayetteville, NC 28303